HUTCHMED Advances Global Early Trials For First-In-Class Conjugates
HUTCHMED’s Guangxi Tai talks to Scrip about the firm’s first-in-class antibody-targeted therapy conjugates and strategies for cross-border partnerships.
Scrip - August 19, 2026

Perimeter Debuts At Intermountain Health With FDA-Approved AI System For Breast Cancer Surgery
Perimeter Medical Imaging AI has commercially launched Claire, the first AI-enabled, PMA-approved intraoperative breast cancer margin assessment system, at two Intermountain Health hospitals. Reimbursement is the next hurdle; the company is also burning cash at a rate that will require a new raise.
Medtech Insight - August 18, 2026

FDA Weathers A Turbulent Year And A Half, Though Long-Term Damage Remains Unclear
The FDA has endured 18 months of instability and upheaval; and though it has met key review targets, the agency’s device center has not been unscathed. But experts differ on the degree of damage the agency has sustained and how effectively it can carry out its public health mandate going forward.
Medtech Insight - August 18, 2026

Cook Medical Phishing, Baylor Genetics Breach Deepen Medtech Cybersecurity Concerns
Cook Medical and Baylor Genetics are the latest in a string of 2026 medtech cyber incidents that also hit Stryker, Intuitive, Medtronic, iRhythm and Abbott.
Medtech Insight - August 18, 2026

US FDA Drug Inspections At Pre-Pandemic Levels; Domestic OIA Citations Exceed Global Average
Foreign inspections still lag, but mutual recognition agreements are helping to fill the gap. If partner nations’ activities are counted, inspections are now above their pre-COVID levels for biopharma facilities.
HBW Insight - August 18, 2026

US FDA Report On Pharma Quality Documents Success In Curbing OTC Contaminations
FDA notes success in responding to contaminations of diethylene glycol and ethylene glycol in OTC drugs and benzene OTC aerosols in its latest drug quality assurance inspections report.
HBW Insight - August 18, 2026

US Cosmetics Industry Pushes Back on China’s Trade-Busting GMP Certificate Requirement
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026

Lawsuit Paid And Patents Delisted Following Teva’s QVAR Inhaler Generics Settlement
A US judge has signed off on Teva's $35m settlement after allegedly delaying inhaler generics.
Generics Bulletin - August 18, 2026

Generic Drug User Fee Agreement Streamlines Meetings, Creates ‘Complex Issue’ Goal Extension
The GDUFA IV commitment letter will rename formal meetings and streamline its structure, as well as create a new goal date extension for complex regulatory issues.
Generics Bulletin - August 18, 2026

GBMA Pushes For PBS Pricing Reform To Stave Off Australian Shortages
Australia’s generics and biosimilars body has called for PBS pricing, stockholding and regulatory reforms to make medicine supply more commercially sustainable and prevent shortages before they reach patients.
Generics Bulletin - August 18, 2026

Expectations Vs. Reality: Formycon Faces Muted Stelara Biosimilar Momentum
Formycon confirmed its full-year revenue guidance of €60m–€70m, leaning on expected growth from the underperforming ustekinumab and far-from-launch but promising pembrolizumab biosimilars.
Generics Bulletin - August 18, 2026

AI-Driven Chinese Biotechs Make Splash With Financing Deals, Again
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
In Vivo - August 18, 2026

IPF Pipeline’s Next Big Readout: Bristol’s Admilparant Pivotal Trial
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
In Vivo - August 18, 2026

Strategic Intent: The Rise Of Mid-Cap Dealmakers
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026